$Tilray Brands(TLRY.US)$ a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, has expanded its medical cannabis offerings in the United Kingdom. Tilray Medical now offers the broadest portfolio of cannabis flower in the UK market today, including a differentiated range of high THC products, cultivated at its EU-GMP-certified facility in Portugal.  Denise Faltischek, Tilray's Chief Strategy Officer, and Head of International Business, said, "The demand for medical cannabis in the UK is growing rapidly. We are incredibly proud to provide patients in the UK with high-quality, consistent medical cannabis products they can rely on and are accessible to them."  Tilray Medical now offers an extensive selection of medical cannabis products including a market leading portfolio of cannabis flowers with THC potencies that span from 10% to 25% and offer a range of different ratios1. Tilray Medical's portfolio in the UK is underpinned by a breadth of cultivars, each with a unique profile of cannabinoids and terpenes, that have been selected to ensure patients can receive both the highest product quality as well as consistency when it comes to supply of their medicinal cannabis products. By offering such a broad range of cannabis flower products in the UK, Tilray Medical hopes to expand the range of treatment options available to patients and ensure prescribers and patients are provided with a safe and reliable choice as they embark on their medical cannabis journey.  In the UK, patients may obtain prescriptions for medical cannabis through their specialist doctor. Tilray Medical supplies the UK and the rest of our international business with EU-GMP certified medical cannabis from our state-of-the-art facilities in Portugal, providing patients with safe and reliable access to high-quality medical cannabis.